Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd

Detailed Description

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-MMAE, which is in clinical trial Phase I for tumors; Trop 2 antibody-conjugated drug that is in pre-clinical studies for triple negative breast cancer, bladder and gastric cancer, and other tumors; and HER2 antibody-drug conjugate, which is in pre-clinical study for tumors. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV; and aminolevulinic acid that is in Phase I clinical trials for acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs comprising Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for Hepatobiliary disease; and JAK1 inhibitor that is in Phase I clinical trial for rheumatoid arthritis. Additionally, it researches and develops pharmaceutical and medical devices; medical diagnostic products; provides related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; and production of freeze-dried powder injections and APIs, as well as invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

Financials